CAR T-cell therapy for CNS lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of CAR T-cell therapy (MB-CART19.1) for people with central nervous system lymphoma (CNSL) that has come back or not responded to treatment. It aims to see if this therapy can help treat the lymphoma in the brain or spinal fluid.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of CNS lymphoma called diffuse large B-cell lymphoma (DLBCL) that has come back or hasn't responded to at least one prior treatment with methotrexate.
- You can have MRI or CT scans, and you can have a lumbar puncture (spinal tap) or Ommaya tap (a way to sample spinal fluid).
- Your kidneys and liver are working well enough, and your oxygen level is normal.
- You are not pregnant or breastfeeding, and you agree to use birth control for one year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a new type of immune therapy (CAR T cells) placed directly into the fluid around the brain to treat central nervous system (CNS) lymphoma. It mainly looks at safety and how well the treatment can control the lymphoma when other CNS treatments have not worked.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
This trial tests a new treatment called Anbalcabtagene Autoleucel (a type of CAR-T cell therapy) for people whose B-cell lymphoma has come back or not responded to treatment, specifically when it affects the brain or spinal cord. The goal is to see if this therapy can help control the disease.
This trial tests a new treatment using specially engineered immune cells from cord blood to target and kill cancer cells in the brain or spine. It is for people whose central nervous system lymphoma has not responded to or has returned after previous treatments.
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
This trial tests a CAR T-cell therapy (MB-CART2019.1) against standard treatment in people with certain types of aggressive B-cell lymphoma that has come back or didn’t respond to the first treatment. It aims to improve how well the lymphoma responds and to check for side effects and safety.
Hear when a new Primary Central Nervous System (CNS) Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.